<DOC>
	<DOCNO>NCT00518310</DOCNO>
	<brief_summary>Idiopathic pulmonary fibrosis ( IPF ) diffuse lung disease , associate histological appearance usual interstitial pneumonia ( UIP ) , inexorably deteriorate clinical course . Prognosis poor , report median survival le 3 year . The prevalence estimate 3 10 per 100.000 different Western population . To date , pharmacological therapy proven alter reverse pathogenic process IPF . Most treatment trial observational case series small patient population randomize , prospective placebo-controlled . Two recent Cochrane review investigate role corticosteroid immunomodulatory agent conclude evidence use IPF . Most current therapy target suppress inflammatory component disease , base theory would chronic alveolar inflammation lead parenchymal remodel fibrosis . Recently , hypothesis gain acceptance suggests fibrosis may result directly alveolar injury , promote abnormal fibrogenic repair mediate fibroblast myofibroblasts . One cytotoxic agent widely use well tolerated management IPF azathioprine . Based upon limited data available single small high quality randomize control trial ( RCT ) , drug appear confer , give conjunction prednisone , marginal long term survival advantage . Since combination therapy associate serious adverse effect , plan design trial low dose corticosteroid azathioprine versus placebo management IPF , evaluate progression-free survival . Our study hypothesis : Combined therapy azathioprine corticosteroid improve progression-free survival patient diagnosis IPF .</brief_summary>
	<brief_title>Azathioprine Prednisone Treatment Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>We evaluate adult patient consecutively refer March 2005 Instituto Nacional del TÃ³rax ( Thorax National Institute ) , Santiago , Chile diagnostic evaluation Pulmonary Fibrosis . The routine evaluation include , indicated , follow step : - History : - Age - Genre - Duration symptom first consultation - Smoking status - Search collagen vascular disease - Family history pulmonary fibrosis - Occupational exposure - Drug ot toxic exposure - Physical examination : search crackle finger club . - Laboratory data : - Complete blood bell count - BUN - Creatinine - Liver enzymes - Antinuclear antigens - Erythrocyte sedimentation rate - Rheumatoid factor - HIV - Antineutrophil cytoplasmic antibody ( appropiate clinical setting ) - Antiglomerular basement antibody ( appropiate clinical setting ) - Modified Medical Research Council Dyspnea Scale ( MMRC ) ( 10 ) - Chronic Respiratory Questionnaire ( CRQ ) ( 11 ) - Pulmonary function test : - Spirometry - Plethismographic lung volume - DLco - Composite physiologic index ( 12 ) - Exercise testing : - Six-Minute Walk Test ( 6MWT ) - Resting 6 minute SpO2 - Presence absence desaturation 88 % low end six minute walk ( 13 ) - Walked distance - Pre post modify Borg dyspnea score - Timed walk test ( 14 ) - Arterial blood gas analysis rest exercise , calculate difference alveolar arterial oxygen tension ( P ( A-a ) O2 ) rest exercise . - Radiologic study : - Chest radiography - HRCT : - Definite probable idiopathic pulmonary fibrosis ( 15 ) : - Definitive criterion : presence lung volume reduction , reticular abnormality , traction bronchiectasis , , basal peripheral predominance ; presence honeycomb basal peripheral predominance ; absence atypical feature usual interstitial pneumonia - micronodules , peribronchovascular nodule , consolidation , isolate ( nonhoneycombing ) cyst , ground-glass attenuation ( present , less extensive reticular opacity ) , mediastinal adenopathy ( present , limited visible chest radiography ) . - Probable criterion : presence bilateral , predominantly basal subpleural reticular pattern subpleural cyst ( honeycomb ) , traction bronchiectasis , absence atypical feature UIP . - Scoring extent lung fibrosis ( 16 ) . - Bronchoscopy : - Bronchoalveolar lavage : cellular analysis CD4/CD8 ratio . - Transbronchial biopsy . - Surgical lung biopsy : - Number - Site/Side - Type surgery : open v thoracoscopic - Histologic feature ( 3 ) Those patient IPF diagnosed basis clinical radiographic criterion alone accord ATS/ERS consensus committee ( 3 ) , and/or biopsy proven histological pattern UIP , select randomization process , sign write informed consent .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>45 79 year age . Clinical symptom IPF least 3 month . Forced vital capacity ( FVC ) 50 90 % predict value . DLco least 35 % predict value . PaO2 &gt; 55 mm Hg breathing ambient air rest . Highresolution compute tomography ( HRCT ) show definite probable criterion IPF . Clinically significant exposure know fibrogenic agent ( bird , mold , hot tube , asbestos , radiation drug know cause pulmonary fibrosis ( amiodarone , nitrofurantoin , bleomicin , etc ) ) . History neurofibromatosis , HermanskyPudlak syndrome , metabolic storage disorder , etc . History fever , weight loss , myalgia , arthralgia , skin rash , arthritis . Active infection within one week enrollment . Alternative cause interstitial lung disease . Ratio force expiratory volume one second ( VEF1 ) FVC le 0.6 use bronchodilator . Residual volume 120 % predict value ( available ) . More 20 % lymphocytes eosinophil bronchoalveolar lavage ( BAL ) ( available ) . Granulomas , infection malignancy transbronchial surgical biopsy ( available ) . Previous therapy azathioprine , prednisolone ( &gt; 0.5 mg/kg/day least 3 month ) , cyclophosphamide novel biotech drug . Unstable cardiovascular neurologic disease . Uncontrolled diabetes . Pregnancy . Lactation . Likelihood death , predict investigator , within next year . White cell blood count &lt; 4000/mm3 . Platelet count &lt; 100000/mm3 . Hematocrit &lt; 30 % &gt; 59 % . Liver enzymes 3 time upper limit normal range . Creatinine level &gt; 1.5 mg/dL . Albumin level &lt; 3 g/dL . Refusal sign inform consent patient guardian .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>Usual interstitial pneumonia</keyword>
	<keyword>Cryptogenic fibrosing alveolitis</keyword>
	<keyword>Therapy</keyword>
	<keyword>Azathioprine</keyword>
	<keyword>Steroids</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Prednisone</keyword>
</DOC>